A vaccine that targets the mucosal surfaces to prevent HIV infection
Official title: Durable HIV Vaccine Targeting Mucosal Epithelium
Funded at Texas Biomedical Research Institute · NIH-11094581 · Data updated 2026-11-12
This study is testing a new type of HIV vaccine that aims to create strong protection right where the virus usually enters the body, using special cells to help build a lasting immune response, which could lead to better health for people at risk of HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Biomedical Research Institute NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project start | August 1, 2022 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $970,600 |
| NIH project number | 3R01AI172539-03S1 |
| Project ID | NIH-11094581 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk of HIV exposure or those who are HIV-negative but may benefit from preventive measures.
✕Less likely to help
Patients who are already HIV-positive or those with compromised immune systems may not benefit from this research.
What this research studies
This research investigates a novel approach to developing a durable HIV vaccine that focuses on the mucosal surfaces where the virus typically enters the body. The vaccine aims to stimulate both local and systemic immune responses, providing a two-tiered defense against HIV infection. By utilizing epithelial stem cells to deliver viral antigens, the vaccine seeks to maintain a long-lasting immune response that can effectively block the virus at its entry point. Patients may benefit from a vaccine that offers enhanced protection against HIV, potentially leading to better health outcomes.
Why it matters
Potential benefit: If successful, this research could lead to a long-lasting vaccine that significantly reduces the risk of HIV infection.
How similar studies have gone: Other research has shown promise in developing vaccines targeting mucosal immunity, suggesting that this approach could be viable.
Where this research is happening
-
Texas Biomedical Research Institute
San Antonio, United States Active
Researchers
- Principal investigator: Gauduin, Marie-Claire Elisabeth — Texas Biomedical Research Institute
- Study coordinator: Gauduin, Marie-Claire Elisabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.